



Director Dealings and Issue of Equity

February 4, 2021

Released : February 04, 2021 07:00

RNS Number : 9374N

MaxCyte, Inc.

04 February 2021

MaxCyte, Inc.
("MaxCyte" or the "Company")

Director Dealings and Issue of Equity

Gaithersburg, Maryland - 4 February 2021: MaxCyte (LSE: MXCT, MXCL), the global cell-based medicines and life sciences company, announces that further to the announcement of a £40 million (approx. \$55 million) Subscription via a private placement of 5,740,000 new shares of common stock (the "**Subscription Announcement**") on 3 February, 2021, Doug Doerfler, Chief Executive Officer and a Founder of the Company, Ron Holtz, Senior Vice President and Chief Accounting Officer and J. Stark Thompson, Non-Executive Chairman, have exercised options in the amount of 755,000 shares of common stock, \$0.01 par, of the Company ("**Common Stock**") ("**Exercise**") in aggregate. The 755,000 new shares of Common Stock issued pursuant to the Exercise ("**New Options Common Stock**") have been sold by Doug Doerfler, Ron Holtz and J. Stark Thompson at a price of 700 pence per Common Stock ("**Sale**").

Following the Exercise and Sale, Mr Doerfler's holding of Common Stock remains unchanged at a total of 433,197 shares and Mr Holtz's holding of Common Stock remains unchanged at a total of 150,251 shares, representing 0.5% and 0.2%, respectively, of the enlarged issued share capital of the Company following the Subscription and the Exercise. Mr. Doerfler, Mr. Holtz and Dr Thompson hold a further 2,313,480, 1,014,892 and 211,333 options over Common Stock respectively.

Total voting rights

Application has been made for admission of the 755,000 New Options Common Stock to trading on AIM, which is anticipated to occur at 8:00am on 8 February 2021 ("**Options Stock Admission**"). The New Options Common Stock will rank *pari passu* with the existing shares of common stock of the Company and will trade in the unrestricted line of Common Stock trading under the symbol MXCT. The total issued stock capital of the Company following the Options Stock Admission and the admission to trading on AIM of the 5,740,000 shares of Subscription Common Stock ("**Subscription Stock Admission**") will be 83,917,169 shares of common stock. Following Option Stock Admission and Subscription Stock Admission, Shareholders in the Company may use this figure as the denominator for the calculations by which they will determine if they are required to notify

their interest in, or a change to their interest in, the stock capital of the Company.

Following Subscription Stock Admission (which comprises First Admission and Second Admission) and Options Stock Admission, the number of unrestricted shares of Common Stock trading under the symbol 'MXCT' will be 73,687,080; the number of restricted shares of Common Stock trading under the symbol 'MXCL' will be 9,900,089 and the number of restricted shares of Common Stock trading under the symbol 'MXCN' will be 330,000.

Save as otherwise defined, capitalised terms used in this announcement have the meanings given to them in the Subscription Announcement.

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 ("MAR").

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

1	Details of the person discharging managerial responsibilities/person closely associated		
a)	Name	Doug Doerfler	
2	Reason for the notification		
a)	Position/status	Chief Executive Officer	
b)	Initial notification/Amendment	Initial notification	
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	MaxCyte, Inc.	
b)	LEI	54930053YHXULRFCU991	
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted		
a)	Description of the financial instrument, type of instrument	Common Stock of \$0.01 each	
b)	Identification Code	US57777K1060	
c)	Nature of the transaction	Exercise of options and Sale of Common Stock by PDMR	
d)	Price(s) and volume(s)	Price(s)	
		Volume(s)	
		N/A	500,000 (option exercise)
		700 pence	500,000 (sale of common stock)

e)	Aggregated information	N/A
	- Aggregated volume	N/A
	- Price	N/A
f)	Date of the transaction	3 February 2021
g)	Place of the transaction	London Stock Exchange, AIM Market (XLON)

1	Details of the person discharging managerial responsibilities/person closely associated	
a)	Name	Ron Holtz
2	Reason for the notification	
a)	Position/status	Senior Vice President and Chief Accounting Officer
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a)	Name	MaxCyte, Inc.
b)	LEI	54930053YHXULRFCU991
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted	
a)	Description of the financial instrument, type of instrument	Common Stock of \$0.01 each
b)	Identification Code	US57777K1060
c)	Nature of the transaction	Exercise of options and Sale of Common Stock by PDMR
d)	Price(s) and volume(s)	Price(s)
		Volume(s)
		N/A
	700 pence	225,000 (sale of common stock)
e)	Aggregated information	N/A
	- Aggregated volume	N/A
	- Price	N/A
f)	Date of the transaction	3 February 2021
g)	Place of the transaction	London Stock Exchange, AIM Market (XLON)

1	Details of the person discharging managerial responsibilities/person closely associated		
a)	Name	J. Stark Thompson	
2	Reason for the notification		
a)	Position/status	Non-Executive Chairman and PDMR	
b)	Initial notification/Amendment	Initial notification	
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	MaxCyte, Inc.	
b)	LEI	54930053YHXULRFCU991	
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted		
a)	Description of the financial instrument, type of instrument	Common Stock of \$0.01 each	
b)	Identification Code	US57777K1060	
c)	Nature of the transaction	Exercise of options and Sale of Common Stock by PDMR	
d)	Price(s) and volume(s)	Price(s)	Volume(s)
		N/A	30,000 (option exercise)
		700 pence	30,000 (sale of common stock)
e)	Aggregated information	N/A	
	- Aggregated volume	N/A	
	- Price	N/A	
f)	Date of the transaction	3 February 2021	
g)	Place of the transaction	London Stock Exchange, AIM Market (XLON)	

For the purposes of MAR, the person responsible for arranging for the release of this Announcement on behalf of the Company is Maher Masoud, General Counsel.

For further information, please contact:

MaxCyte Inc.

+1 301 944 1660

Doug Doerfler, Chief Executive Officer

Ron Holtz, Chief Accounting Officer

Nominated Adviser and Joint Corporate Broker +44 (0)20 7886 2500
Panmure Gordon
Emma Earl
Freddy Crossley
Corporate Broking
Rupert Dearden

Joint Corporate Broker +44 (0)20 7260 1000
Numis Securities Limited
James Black
Duncan Monteith

Joint Corporate Broker +44 (0) 20 7710 7600
Stifel Nicolaus Europe Limited

Healthcare Investment Banking
Nicholas Moore / Ben Maddison / Samira Essebiyea
Corporate Broking
Nick Adams
Financial PR Adviser

Consilium Strategic Communications +44 (0)203 709 5700
maxcyte@consilium-comms.com
Mary-Jane Elliott
Chris Welsh

About MaxCyte

MaxCyte is a world-leading provider of cell-engineering enabling technology and is responsible for helping to bring next-generation cell and gene-editing therapies to life. The Company's technology is deployed by leading drug developers worldwide, including all of the top ten global biopharmaceutical companies. MaxCyte licences have been granted for more than 140 cell therapy programmes, with more than 100 licensed for clinical use, and the Company has now entered into twelve clinical/commercial license partnerships with leading cell therapy and gene editing developers. MaxCyte was founded in 1998, is listed on the London Stock Exchange (LSE: MXCT, MXCL) and is headquartered in Gaithersburg, Maryland, US. For more information, visit www.maxcyte.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHTJMBTMTJMTPB